Medical AI Alliance
← Company Index
Medical DevicesKOSDAQ 21608078 approvals3 trials

JETEMA Co.,Ltd.

Official website

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

As of 2026-10-10, JETEMA Co.,Ltd. has 75 Korean MFDS device approvals, 3 Korean MFDS drug approvals, 9 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

JETEMA Co.,Ltd. was founded in 2009 and listed on KOSDAQ in 2019 as a medical device company. It develops and manufactures hyaluronic acid dermal fillers, botulinum toxin-based biopharmaceuticals for facial aesthetics, and lifting threads for tissue suturing and facial fixation; its botulinum toxin product Jetema The Toxin Inj. 100U, indicated for glabellar line improvement, received marketing approval in December 2024 and launched domestically in March 2025. The company signed license-out agreements worth roughly KRW 600 billion combined with partners in Brazil (2020) and China (2022), a five-year toxin export contract worth about KRW 40 billion with a Thai partner in H1 2024, and established its US subsidiary Jetema USA Inc.; consolidated 2025 revenue was KRW 76.9 billion (up 12.2% year-on-year) with operating profit of KRW 3.8 billion (down 7.1% year-on-year).

Products & technology

  • Jetema The Toxin Inj. 100UGlabellar line improvement
  • Hyaluronic acid dermal fillerFacial aesthetics (tissue-repair biomaterial)
  • Lifting threadTissue suturing and facial fixation

Regulatory approvals

data.go.kr

3 Korean MFDS drug approvals · 2020–2024 / 75 Korean MFDS device approvals · 1999–2025

  • MFDSGraft/prosthesis2025-10-24
    Product approval · Class 4제허 25-717 호
  • MFDSGraft/prosthesis2025-10-24
    Product approval · Class 4제허 25-716 호
  • MFDSPolydioxanone suture2025-06-10
    Product approval · Class 4제허 25-379 호
  • MFDS drugJETEMA THE TOXIN Inj. 100U(Clostridium Botulinum Toxin Type A)2024-12-05
    Drug · Prescription · Approval202402879
  • MFDSGraft/prosthesis, biomaterial2024-11-19
    Product approval · Class 4제허 24-813 호
  • MFDSPolydioxanone suture2024-09-04
    Product approval · Class 4제허 24-607 호
  • MFDSPolydioxanone suture2024-07-15
    Product approval · Class 4제허 24-482 호
  • MFDSGraft/prosthesis2024-05-22
    Product approval · Class 4제허 24-347 호
  • MFDSThread for facial tissue fixation, absorbable or non-absorbable2023-05-31
    Product approval · Class 4제허 23-627 호
  • MFDSThread for facial tissue fixation, absorbable or non-absorbable2023-05-31
    Product approval · Class 4제허 23-625 호
  • MFDSPolydioxanone suture2023-05-25
    Product approval · Class 4제허 23-612 호
  • MFDSPolydioxanone suture2023-05-25
    Product approval · Class 4제허 23-611 호
Show 66 more
  • MFDSGraft/prosthesis, biomaterial2023-03-02
    Product approval · Class 4제허 23-180 호
  • MFDSGraft/prosthesis, biomaterial2023-01-30
    Product approval · Class 4제허 23-66 호
  • MFDSGraft/prosthesis, biomaterial2023-01-30
    Product approval · Class 4제허 23-65 호
  • MFDSGraft/prosthesis, biomaterial2022-03-14
    Product approval · Class 4제허 22-174 호
  • MFDS drugJETEMA THE TOXIN Inj. 200U (Clostridium Botulinum toxin type A)2021-10-29
    Drug · Prescription · Approval202107200
  • MFDSGraft/prosthesis, biomaterial2021-03-31
    Product approval · Class 4제허 21-235 호
  • MFDSGraft/prosthesis, biomaterial2021-03-31
    Product approval · Class 4제허 21-234 호
  • MFDSGraft/prosthesis2020-06-26
    Product approval · Class 4제허 20-517 호
  • MFDS drugJETEMA THE TOXIN Inj. 100U (Clostridium Botulinum toxin type A)(for export)2020-06-04
    Drug · Prescription · Approval202004236
  • MFDSGraft/prosthesis, biomaterial2020-02-03
    Product approval · Class 4제허 20-72 호
  • MFDSPolydioxanone suture2019-10-02
    Product approval · Class 4제허 19-628 호
  • MFDSGraft/prosthesis, biomaterial2019-07-09
    Product approval · Class 4제허 19-445 호
  • MFDSGraft/prosthesis, biomaterial2019-07-09
    Product approval · Class 4제허 19-444 호
  • MFDSGraft/prosthesis, biomaterial2019-02-21
    Product approval · Class 4수허 19-49 호
  • MFDSGraft/prosthesis, biomaterial2019-02-21
    Product approval · Class 4수허 19-48 호
  • MFDSPolydioxanone suture2018-12-04
    Product approval · Class 4제허 18-771 호
  • MFDSThread for facial tissue fixation, absorbable or non-absorbable2018-04-18
    Product approval · Class 4제허 18-269 호
  • MFDSThread for facial tissue fixation, absorbable or non-absorbable2018-04-18
    Product approval · Class 4제허 18-268 호
  • MFDSThread for facial tissue fixation, absorbable or non-absorbable2018-03-05
    Product approval · Class 4제허 18-148 호
  • MFDSThread for facial tissue fixation, absorbable or non-absorbable2018-03-05
    Product approval · Class 4제허 18-147 호
  • MFDSSuture, absorbable2018-02-13
    Product approval · Class 4제허 18-89 호
  • MFDSPolydioxanone suture2018-02-13
    Product approval · Class 4제허 18-86 호
  • MFDSGraft/prosthesis, biomaterial2017-09-29
    Product approval · Class 4제허 17-766 호
  • MFDSGraft/prosthesis, biomaterial2017-09-29
    Product approval · Class 4제허 17-765 호
  • MFDSGraft/prosthesis, biomaterial2017-08-02
    Product approval · Class 4제허 17-594 호
  • MFDSGraft/prosthesis, biomaterial2017-03-21
    Product approval · Class 4제허 17-203 호
  • MFDSNeedle, aspiration/injection, reusableRevoked2015-06-18
    Product approval · Class 1서울 제신 15-225 호
  • MFDSIndirect infusion deviceRevoked2015-06-18
    Product approval · Class 1서울 제신 15-224 호
  • MFDSIndirect infusion deviceRevoked2015-03-17
    Product approval · Class 1서울 제신 15-99 호
  • MFDSIndirect infusion deviceRevoked2015-03-17
    Product approval · Class 1서울 제신 15-98 호
  • MFDSGraft/prosthesis, biomaterial2015-03-17
    Product approval · Class 4제허 15-365 호
  • MFDSPharmacy compounding system, manually-operatedRevoked2015-03-11
    Product approval · Class 2제인 15-342 호
  • MFDSDressing, adhesion barrierRevoked2014-12-19
    Product approval · Class 3제허 14-3195 호
  • MFDSGraft/prosthesis, biomaterialRevoked2014-11-18
    Product approval · Class 4제허 14-2301 호
  • MFDSGraft/prosthesis, biomaterial2014-10-01
    Product approval · Class 4제허 14-1768 호
  • MFDSGraft/prosthesis, biomaterial2014-08-27
    Product approval · Class 4수허 14-2569 호
  • MFDSIndirect infusion deviceRevoked2013-07-19
    Product approval · Class 1서울 제신 13-205 호
  • MFDSIndirect infusion deviceRevoked2013-07-19
    Product approval · Class 1서울 제신 13-204 호
  • MFDSIndirect infusion deviceRevoked2012-12-06
    Product approval · Class 1서울 제신 12-288 호
  • MFDSLaser surgical unit, othersRevoked2012-10-08
    Product approval · Class 3수허 12-1423 호
  • MFDSIndirect infusion deviceRevoked2011-09-15
    Product approval · Class 1서울 제신 11-189 호
  • MFDSIndirect infusion deviceRevoked2011-04-08
    Product approval · Class 1서울 제신 11-56 호
  • MFDSOximeter catheter, fibreopticRevoked2010-11-05
    Product approval · Class 2수허 10-1173 호
  • MFDSIndirect infusion deviceRevoked2010-10-26
    Product approval · Class 1서울 제신 10-228 호
  • MFDSLaser surgical unit, othersRevoked2010-06-29
    Product approval · Class 3수허 10-664 호
  • MFDSLaser surgical unit, diodeRevoked2009-11-18
    Product approval · Class 3수허 09-1187 호
  • MFDSLaser surgical unit, othersRevoked2009-11-12
    Product approval · Class 3제허 09-939 호
  • MFDS광선조사기Revoked2009-03-27
    Product approval · Class 3제허 09-205 호
  • MFDS레이저수술기Revoked2008-09-26
    Product approval · Class 3수허 08-927 호
  • MFDS의약품주입용기구Revoked2008-03-21
    Product approval · Class 1제신 08-58 호
  • MFDS레이저수술기Revoked2008-03-11
    Product approval · Class 3제허 08-139 호
  • MFDSLaser surgical unit, othersRevoked2007-11-13
    Product approval · Class 3수허 07-980 호
  • MFDS레이저수술기Revoked2007-05-18
    Product approval · Class 3제허 07-274 호
  • MFDS고주파자극기Revoked2006-11-06
    Product approval · Class 3제허 06-826 호
  • MFDS레이저수술기Revoked2006-04-28
    Product approval · Class 3수허 06-440 호
  • MFDS광선조사기Revoked2006-01-17
    Product approval · Class 3제허 06-47 호
  • MFDS레이저수술기Revoked2005-09-08
    Product approval · Class 3제허 05-731 호
  • MFDS광선조사기Revoked2004-05-31
    Product approval · Class 3제허 04-547 호
  • MFDS의약품주입용기구Revoked2004-04-16
    Product approval · Class 2제허 04-378 호
  • MFDS레이저수술기Revoked2004-04-09
    Product approval · Class 3수허 04-479 호
  • MFDS의약품주입용기구Revoked2004-02-25
    Product approval · Class 2제허 04-187 호
  • MFDS레이저수술기Revoked2002-07-26
    Product approval · Class 2수허 02-844 호
  • MFDS의료용석고절단기Revoked2001-12-12
    Product approval · Class 2제허 01-727 호
  • MFDS의약품주입용기구Revoked2000-02-28
    Product approval · Class 2제허 00-75 호
  • MFDS의약품주입용기구Revoked2000-02-28
    Product approval · Class 2제허 00-76 호
  • MFDS의약품주입용기구Revoked1999-12-27
    Product approval · Class 2제허 99-378 호

Clinical trials

data.go.kr

3 MFDS clinical trial authorisations · 2020–2023 (Phase 1 2 · Phase 3 1)

  • Phase 1제테마더톡신주 100단위(JTM201)2023-05-08

    2 trial sites

  • Phase 3제테마더톡신주 100단위(JTM201)2022-04-01

    3 trial sites

  • Phase 1제테마더톡신주 100단위(JTM201)2020-08-03

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

보툴리눔 톡신 Type E · 안면미용 및 치료용 다양한 적응증(상처치유, 치핵절제, 치과임플란트, 관절치환술, 여드름, 과민성대장증후군, 근골격계 통증 등) · 적응증 및 차세대 제형 개발 단계 · Effect onset within 24 hours and duration of 2-4 weeks; being developed as a non-narcotic analgesic alternative with potential for expansion into multiple indications

보툴리눔 톡신(국내) · 상지 근육경직 치료 · 임상 1상 완료 · Completed Phase 1; preparing entry into the therapeutic market

보툴리눔 톡신(중국) · 미간 주름 개선 · 임상 1상 종료, 임상 3상 진행중

보툴리눔 톡신(미국) · 미간 주름 개선 · 임상 2상 완료(2025년 12월)

히알루론산 필러 안면볼륨 · 안면볼륨 개선 · 2024년 5월 임상시험계획 승인, 임상시험 진행중

히알루론산 필러 팔자주름 · 팔자주름 개선 · 2025년 7월 임상시험계획 승인, 임상시험 진행중

히알루론산 필러 미세주름 · 미세주름 개선 · 임상시험계획 단계

Key disclosures

KRX KIND via OpenDART
Show 3 more events

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 55 more patents

AI reads

MAA server logs · IP-verified
171
Times AI engines pulled JETEMA Co.,Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

170
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

8
live 0
Last 7 days
127
live 0
Last 30 days
171
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot134
  • GoogleGoogleOther27
  • PerplexityPerplexityBot6
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for JETEMA Co.,Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsMedical Devices

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

DongBang Medical Co., Ltd.10 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

METABIOMED.CO.,LTD6 shared

KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.

HANS BIOMED CORPORATION5 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

WON TECH CO.,Ltd.5 shared

Founded in 2019 and KOSDAQ-listed the same year, WON TECH makes aesthetic laser, RF, and HIFU devices including Oligio and Picocare.

PharmaResearch Co., Ltd.5 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

BioPlus Co., Ltd4 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

Samyang Biopharm Corporation4 shared

Founded and KOSPI-listed in 2025, Samyang Biopharm develops medical devices, pharmaceuticals, and new drug candidates.

Chabiotech Co.,Ltd.4 shared

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

Hironic Co.,Ltd4 shared

KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.

BNC KOREA, Inc.4 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

BTB Korea Co.,Ltd3 shared

KOSDAQ-listed aesthetic medical device company producing PICO, DUAL HI, and other anti-aging and body-contouring devices.

Humedix Co., Ltd.3 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition